Analysis of the gene is recommended in cases of gastrointestinal stromal tumours (GIST), brain tumours (glioma), a type of liver cancer (hepatocellular carcinoma; HCC), renal cell carcinoma, chronic myeloid leukaemia (CML), and melanomas.

KIT-mutant tumours can be treated efficiently using two types of medicines for targeted therapy: Bcr-Abl tyrosine kinase inhibitors for chronic myeloid and acute lymphoid leukaemia and GIST patients and another type of receptor tyrosine kinase inhibitor to treat those GIST patients who have already become resistant to the Bcr-Abl tyrosine kinase inhibitor.